| |
Total
|
Q1
|
Q2
|
Q3
|
Q4
|
P
|
|---|
|
Participants
|
54,098
|
13,524
|
13,525
|
13,525
|
13,524
| |
|
Age (years)
|
49.03 ± 11.84
|
44.88 ± 10.57
|
46.99 ± 11.50a
|
50.71 ± 11.89ab
|
53.54 ± 11.42abc
|
< 0.01
|
|
Male, N (%)
|
41,157 (76.08)
|
9561 (70.70)
|
10,782 (79.72)
|
10,506 (77.68)
|
10,308 (76.22)
|
< 0.01
|
|
BMI (kg/m2)
|
25.01 ± 3.16
|
24.03 ± 3.04
|
24.84 ± 3.14a
|
25.29 ± 3.10ab
|
25.87 ± 3.07abc
|
< 0.01
|
|
SBP (mmHg)
|
129.44 ± 16.88
|
123.71 ± 15.66
|
128.33 ± 15.64a
|
131.63 ± 16.93ab
|
134.07 ± 17.41abc
|
< 0.01
|
|
DBP (mmHg)
|
83.54 ± 9.22
|
81.19 ± 9.14
|
83.50 ± 8.86a
|
84.43 ± 9.21ab
|
85.06 ± 9.20abc
|
< 0.01
|
|
HDL-C (mmol/L)
|
1.54 ± 0.32
|
1.59 ± 0.32
|
1.55 ± 0.30a
|
1.53 ± 0.32ab
|
1.49 ± 0.33abc
|
< 0.01
|
|
LDL-C (mmol/L)
|
2.49 ± 0.64
|
2.33 ± 0.64
|
2.49 ± 0.60a
|
2.54 ± 0.62ab
|
2.62 ± 0.64abc
|
< 0.01
|
|
FBG (mmol/L)
|
5.54 ± 1.38
|
5.09 ± 0.68
|
5.35 ± 0.96a
|
5.58 ± 1.31ab
|
6.15 ± 1.99abc
|
< 0.01
|
|
TG (mmol/L)
|
1.34 (0.98–1.96)
|
0.97 (0.75–1.25)
|
1.32 (1.01–1.75)a
|
1.45 (1.07–2.19)ab
|
1.87 (1.37–2.72)abc
|
< 0.01
|
|
hs-CRP (mg/L)
|
1.45 (0.77–2.93)
|
1.35 (0.67–2.80)
|
1.34 (0.71–2.69)a
|
1.49 (0.80–2.98)ab
|
1.64 (0.92–3.19)abc
|
< 0.01
|
|
TyG index2006
|
8.64 ± 0.69
|
8.22 ± 0.53
|
8.56 ± 0.57a
|
8.74 ± 0.65ab
|
9.04 ± 0.70abc
|
< 0.01
|
|
TyG index2008
|
8.66 ± 0.68
|
8.19 ± 0.50
|
8.56 ± 0.51a
|
8.76 ± 0.61ab
|
9.15 ± 0.69abc
|
< 0.01
|
|
TyG index2010
|
8.69 ± 0.67
|
8.30 ± 0.51
|
8.61 ± 0.55a
|
8.77 ± 0.65ab
|
9.09 ± 0.70abc
|
< 0.01
|
|
Cum-TyG
|
34.93 ± 1.48
|
30.05 ± 1.62
|
33.23 ± 0.70a
|
35.88 ± 0.87ab
|
40.56 ± 2.61abc
|
< 0.01
|
|
Current smoking, N (%)
|
20,711 (38.28)
|
5314 (39.29)
|
5465 (40.41)
|
5111 (37.79)ab
|
4821 (35.65)abc
|
< 0.01
|
|
Current drinker, N (%)
|
19,167 (35.43)
|
4789 (35.4)
|
4952 (36.61)
|
4769 (35.26)
|
4657 (34.44)ab
|
< 0.01
|
|
Physical activity, N (%)
|
7833.0 (14.48)
|
1584 (11.71)
|
1621 (11.99)
|
2163 (15.99)ab
|
2465 (18.23)abc
|
< 0.01
|
|
Hypertension, N (%)
|
25,880 (47.84)
|
4649 (34.38)
|
6062 (44.82)a
|
7115 (52.61)ab
|
8054 (59.55)abc
|
< 0.01
|
|
Diabetes mellitus, N (%)
|
6022 (11.13)
|
470 (3.48)
|
930 (6.88)a
|
1605 (11.87)ab
|
3017 (22.31)abc
|
< 0.01
|
|
Antihypertensive drugs, N (%)
|
8397 (15.5)
|
1354 (10.01)
|
2007 (14.84)a
|
2371 (17.53)ab
|
2665 (19.71)abc
|
< 0.01
|
|
Hypoglycemic drugs, N (%)
|
3125 (5.78)
|
239 (1.77)
|
453 (3.35)a
|
772 (5.71)ab
|
1661 (12.3)abc
|
< 0.01
|
|
Lipid-lowering drugs, N (%)
|
905 (1.67)
|
123 (0.91)
|
163 (1.21)a
|
226 (1.67)ab
|
393 (2.91)abc
|
< 0.01
|
- P, comparison of baseline characteristics between different TyG index groups
- BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, TG triglyceride, hs-CRP high-sensitivity C reactive protein, TyG index triglyceride-glucose index
- aP < 0.05, compare with Q1 group. bP < 0.05, compare with Q2 group. cP < 0.05, compare with Q3 group
